Printer Friendly

MAGAININ PHARMACEUTICALS ANNOUNCES DISCOVERY OF FIRST STEROID HOST-DEFENSE ANTIBIOTIC

 MAGAININ PHARMACEUTICALS ANNOUNCES DISCOVERY
 OF FIRST STEROID HOST-DEFENSE ANTIBIOTIC
 PLYMOUTH MEETING, Pa., June 29 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced the discovery of the first steroid host-defense antibiotic which was isolated from the shark.
 The company is actively developing novel systemic broad-spectrum antibiotics based on this discovery as a prime focus of the newly created Magainin Research Institute.
 Patent applications have been filed preceding the publication of this discovery in a major scientific journal later this year.
 "All antibiotic host-defense systems previously discovered have been peptides," said Jay Moorin, president of Magainin. "The discovery of this unique steroid host-defense system could open a new era in the development of antibiotics that can treat human disease. Magainin Pharmaceuticals is applying its drug discovery team to the development of systemic antibiotics based on this discovery as well as peptide based host-defense systems."
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of novel host-defense pharmaceuticals for treatment of infections, wounds and cancer. Later this year, the company expects to launch human clinical trials for MSI-78, its broad spectrum topical antibiotic.
 -0- 6/29/92
 /CONTACT: Scott Horvitz of Magainin Pharmaceuticals, 215-941-5231, or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals/
 (MAGN) CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU: PDT


PS-CK -- NY042 -- 4685 06/29/92 11:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1992
Words:226
Previous Article:MCI VISION OFFERS BUSINESSES COMPREHENSIVE LONG DISTANCE SERVICE FOR ALL CALLING NEEDS
Next Article:PSE&G PARTICIPATES IN PILOT PROGRAM
Topics:


Related Articles
MAGAININ PHARMACEUTICALS ANNOUNCES RESIGNATION
MAGAININ PHARMACEUTICALS ANNOUNCES FORMATION OF NEW INSTITUTE TO BE DIRECTED BY DR. MICHAEL ZASLOFF
MAGAININ PHARMACEUTICALS INC. ANNOUNCES MANUFACTURING PROCESS BREAKTHROUGH FOR ITS LEAD DRUG, MSI-78
SCIENTISTS ISOLATE NEW ANTIBIOTICS FROM SHARK
MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR SQUALAMINE
MAGAININ'S LEAD DRUG CANDIDATE TO ENTER PIVOTAL PHASE IIB/III CLINICAL TRIALS
MAGAININ ANNOUNCES THE ISSUANCE OF THREE PATENTS
Magainin Announces Successful MSI-78 Phase III Trial Results
Magainin Announces Cytolex Collaboration with SmithKline Beecham in North America
Magainin Announces Successful Results of Second Pivotal Trial For Cytolex (MSI-78)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters